Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Tenax Therapeutics, Inc.

  • Anthony DiTonno, Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. (TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing of drugs that address diseases with high unmet medical need. Tenax has secured the North American rights to develop and commercialize levosimendan from the originator company, Orion Corporation of Espoo Finland. Levosimendan is a calcium sensitizer and K-ATP channel opener that works through a unique triple mechanism of action. It is approved in over 60 countries as an intravenous treatment for acute decompensated heart failure. However, levosimendan is not available in the United States or in Canada. Tenax plans to advance the development of Levosimendan for the treatment of pulmonary hypertension associated with heart failure and preserved ejection fraction (PH-HFpEF). Tenax plans to initiate a Phase 2 trial in PH-HFpEF patients in the next few months.

  • Date:Tuesday, February 12
  • Time:2:15 PM - 2:30 PM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23468
  • Goal for Presentation:Exposure and investor update
  • Company Website:http://www.tenaxthera.com/
  • Company HQ City:Morrisville
  • Company HQ State:North Carolina
  • Company HQ Country:United States
  • Market Cap:$4.71M
  • Ticker:TENX
  • Exchange:NASDAQ
  • CEO/Top Company Official:Anthony DiTonno
  • Main Therapeutic Focus:Respiratory
  • Lead Product in Development:Levosimendan
  • Development Phase of Primary Product:Phase II
  • Additional Information/Comments: While approved treatment alternatives exist for other types of pulmonary hypertension (e.g. pulmonary arterial hypertension, PAH), no drugs are approved or been shown effective for the treatment of PH- HFpEF. The various drugs approved for PAH generated over $5 Billion in global sales in 2016. Since none of these PAH approved drugs are effective or approved to treat PH-HFpEF patients, an approval for levosimendan in PH-HFpEF will grow the market substantially.
Speakers
Anthony DiTonno
Tenax Therapeutics, Inc.
Back